Scienture Holdings (SCNX) Registration filing summary

Company overview and business model

• Historically operated health services IT and pharmaceutical wholesale, serving government, hospitals, clinics, and pharmacies nationwide.

• Acquired a specialty pharma subsidiary in July 2024, focusing on CNS and cardiovascular therapeutics, with a pipeline targeting hypertension, migraine, pain, and thrombosis.

• Recent restructuring included transferring Integra Pharma Solutions to a subsidiary and planning to dissolve telehealth assets.

Financial performance and metrics

• As of December 3, 2024, 8,730,366 shares of common stock were outstanding, with additional shares issuable upon exercise of warrants, options, and conversion of preferred stock.

• Received $3,000,000 in gross proceeds from the first tranche of a convertible debenture sale in November 2024.

Use of proceeds and capital allocation

• May receive up to $50,000,000 in gross proceeds from the ELOC Purchase Agreement, to be used for general corporate and working capital purposes.

• Management retains broad discretion over capital allocation from ELOC proceeds.